Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: A 6-month follow-up study

Eye

Volumn 19, Issue 6, 2005, Pages 625-630

  Chan, C K M ^a   Fan, D S P ^a   Chan, Wai Man ^a   Lai, W W ^a   Lee, V Y W ^a   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Intraocular pressure; Intravitreal triamcinolone; Specular microscopy

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CATARACT; CAUCASIAN; CELL COUNT; CHINESE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORNEA DISEASE; CORNEA ENDOTHELIUM; DRUG DOSE REGIMEN; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LENS IMPLANTATION; MALE; OPTIC NERVE LESION; PATIENT MONITORING; PHACOEMULSIFICATION; PREOPERATIVE PERIOD; RETINA DISEASE; SPECULAR MICROSCOPY; STATISTICAL SIGNIFICANCE;

EID: 21244461882     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701585     Document Type: Article

References (28)

1. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.
2. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.
3. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525.
4. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: 419-425.
5. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29: 2-6.
6. Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003; 135: 246-249.
7. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001; 119: 1380-1383.
8. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003; 23: 113-116.
9. Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003; 136: 739-741.
10. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785-788.
11. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190-195.
12. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZJ Ophthalmol 1999; 27: 431-432.
13. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-27.
14. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34: 386-390.
15. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972-974.
16. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-1282.
17. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003; 121: 271-273.
18. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
19. Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma 1995; 4: 354-369.
20. Yeung CK, Kwok PC, Chan CK, Pang CP, Lam DS. The cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004 (in press).
21. Yeung CK, Kwok PC, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003; 44: 5293-5300.
22. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters III GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110: 681-686.
23. Hansen MK. Clinical comparison of the XPERT non-contact tonometer and the conventional Goldmann applanation tonometer. Acta Ophthalmol Scand 1995; 73: 176-180.
24. Popovich KS, Shields MB. A comparison of intraocular pressure measurements with the XPERT noncontact tonometer and Goldmann applanation tonometry. J Glaucoma 1997; 6: 44-46.
25. Jonas JB, Kreissig I, Hugger P, Sander G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87: 462-468.
26. Bourne WM, Kaufman HE. Cataract extraction and the corneal endothelium. Am J Ophthalmol 1976; 82: 44-47.
27. Laule A, Cable MK, Hoffman CE, Hanna C. Endothelial cell population changes of human cornea during life. Arch Ophthalmol 1978; 96: 2031-2035.
28. Kohnen T. Corneal endothelium: an important structure for cataract and refractive procedures. J Cataract Refract Surg 1997; 23: 967-968.